Global Respiratory Partnering Report 2014-2019: Deal Trends, Players and Financials - ResearchAndMarkets.com

DUBLIN--()--The "Global Respiratory Partnering 2014-2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Respiratory Partnering 2014 to 2019 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2014. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report Scope

  • Trends in Respiratory dealmaking in the biopharma industry since 2014
  • Analysis of Respiratory deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Respiratory deal contract documents
  • Comprehensive access to over 300 Respiratory deal records
  • The leading Respiratory deals by value since 2014
  • Most active Respiratory dealmakers since 2014

The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2014 to 2019, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Respiratory dealmaking

2.1. Introduction

2.2. Respiratory partnering over the years

2.3. Respiratory partnering by deal type

2.4. Respiratory partnering by industry sector

2.5. Respiratory partnering by stage of development

2.6. Respiratory partnering by technology type

2.7. Respiratory partnering by therapeutic indication

Chapter 3 - Financial deal terms for Respiratory partnering

3.1. Introduction

3.2. Disclosed financials terms for Respiratory partnering

3.3. Respiratory partnering headline values

3.4. Respiratory deal upfront payments

3.5. Respiratory deal milestone payments

3.6. Respiratory royalty rates

Chapter 4 - Leading Respiratory deals and dealmakers

4.1. Introduction

4.2. Most active in Respiratory partnering

4.3. List of most active dealmakers in Respiratory

4.4. Top Respiratory deals by value

Chapter 5 - Respiratory contract document directory

5.1. Introduction

5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Respiratory therapeutic target

Appendices

Appendix 1 - Directory of Respiratory deals by company A-Z 2014 to 2019

Appendix 2 - Directory of Respiratory deals by deal type 2014 to 2019

Appendix 3 - Directory of Respiratory deals by stage of development 2014 to 2019

Appendix 4 - Directory of Respiratory deals by technology type 2014 to 2019

For more information about this report visit https://www.researchandmarkets.com/r/926wei

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900